IGM Biosciences’ stock tumbles as analysts weigh in on pivot plan with dismay

IGM Biosciences Inc.’s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company’s pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower their ratings.

Previous post Workers are quitting at the lowest rate since the pandemic as jobs get harder to find
Next post PepsiCo to pay $1.2 billion to buy Siete, to boost multicultural food offering